|
|
News Breaks | | | | October 11, 2012 | | 06:10 EDT |  | CELG | Celgene pullback on Revlimid report overdone, says William Blair
William Blair believes the sell-off yesterday in shares of Celgene following the release of a European Public Assessment Report regarding Revlimid was overdone. The firm views Revlimid's benefit/risk profile as compelling as keeps an Outperform rating on Celgene. | |
|
News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks. |
|
|
| May 24, 2013 | | 07:20 EDT | | CELG | Celgene, Gilead, and Biogen could go much higher, says Bernstein
 Subscribe for More Information | | | May 23, 2013 | | 07:37 EDT |  | CELG | Celgene says FDA grants priority review for ABRAXANE sNDA
Subscribe for More Information | | | May 20, 2013 | | 09:51 EDT |  | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. | | | May 17, 2013 | | 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | |
|
|
|
|
|
|
